# Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract

> **NCT04617756** · PHASE2 · RECRUITING · sponsor: **Centre Hospitalier Universitaire de Nīmes** · enrollment: 50 (estimated)

## Conditions studied

- Urothelial Carcinoma
- Cancer

## Interventions

- **DRUG:** Patients receiving neoadjuvant therapy before radical nephrectomy

## Key facts

- **NCT ID:** NCT04617756
- **Lead sponsor:** Centre Hospitalier Universitaire de Nīmes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-29
- **Primary completion:** 2025-01-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04617756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04617756, "Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04617756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*